Lily Li, PhD

Managing Director

Dr. Lily Yi Li serves as the Managing Director of Sixty Degree Capital, where she has established herself as an accomplished leader within the healthcare sector, specializing in drug discovery and healthcare services across Europe, the United States, and Asia. With her profound expertise, Lily brings deep operating and scientific capabilities to Sixty Degree Capital, enabling her to lead successful portfolios, programs, and teams.

Since joining Sixty Degree in 2017, Lily has been at the forefront of healthcare investments, overseeing a remarkable portfolio of companies, including notable names such as Schrödinger (SDGR), Arcellx (ACLX), Monte Rosa (GLUE), Cincor Pharma (CINC, Acquired), Northern Biologics (Acquired), Engage Therapeutics (Acquired), Turnstone Biologics (TSBX), Korro Bio (KRRO), Thrive Health, Everside Health, Inspirna, Nextpoint Therapeutic, Reflexion Medicine, and many more.

Prior to her role at Sixty Degree Capital, Lily garnered invaluable experience as a pharmaceutical scientist, specializing in formulation, CMC, pharmaceutical modeling, and GMP system/plant design. She holds a Ph.D. in Pharmaceutical Science, with a primary focus on Alzheimer’s Research, from the University of Toronto. Both her undergraduate and master’s degrees were also earned at the University of Toronto.